More advanced stages of cutaneous melanoma are usually diagnosed among unmarried patients, especially men and those younger than 68 years of age, even in visible sites such as the face, according to a US study. In addition, these patients have worse survival independent of stage.
The investigational JAK1* selective inhibitor abrocitinib was effective and well-tolerated in adolescents and adults with moderate-to-severe atopic dermatitis (AD), the phase III JADE MONO-2 trial has shown.
The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate 238 trial presented at ESMO 2020.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.